Provided by Tiger Trade Technology Pte. Ltd.

Acurx Pharmaceuticals, LLC*

3.76
-0.2500-6.23%
Post-market: 3.73-0.0300-0.80%19:59 EDT
Volume:250.28K
Turnover:924.38K
Market Cap:10.73M
PE:-0.71
High:3.96
Open:3.92
Low:3.55
Close:4.01
52wk High:21.00
52wk Low:1.33
Shares:2.86M
Float Shares:2.42M
Volume Ratio:0.40
T/O Rate:10.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.3200
EPS(LYR):-17.4507
ROE:-270.80%
ROA:-87.59%
PB:2.04
PE(LYR):-0.22

Loading ...

Acurx files to sell 750,000 shares of common stock for holders

TIPRANKS
·
Feb 03

Acurx Pharmaceuticals Granted New U.S. Patent for DNA Polymerase IIIC Inhibitors

Reuters
·
Feb 02

Acurx Pharmaceuticals and Leiden University Medical Center Secure $375,000 Health~Holland Grant for Antibiotic Research

Reuters
·
Nov 18, 2025

Acurx Pharma Q3 net loss narrows to $2 mln

Reuters
·
Nov 12, 2025

Acurx Pharmaceuticals reports third quarter cash position of $5.9 million

Reuters
·
Nov 12, 2025

Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate

Benzinga
·
Nov 12, 2025

Press Release: Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Dow Jones
·
Nov 12, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

Acurx announces publication of results from ibezapolstat study

TIPRANKS
·
Nov 10, 2025

Acurx Reveals Breakthrough DNA pol IIIC Inhibitor Targeting Drug-Resistant Bacteria

Reuters
·
Nov 10, 2025

Acurx Pharmaceuticals Reports Phase 2 Success for Ibezapolstat in C. difficile Treatment

Reuters
·
Nov 10, 2025

Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025

Reuters
·
Oct 28, 2025

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

THOMSON REUTERS
·
Oct 27, 2025

Acurx files to sell 585,000 shares of common stock for holders

TIPRANKS
·
Oct 21, 2025

Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics

Reuters
·
Oct 09, 2025

Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?

TIPRANKS
·
Oct 08, 2025

Top Premarket Gainers

MT Newswires Live
·
Oct 08, 2025

Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 30, 2025

Acurx Announces Positive Opinion From Ema on Pediatric Investigation Plan for Ibezapolstat Use in Children With C. Difficile Infection

THOMSON REUTERS
·
Sep 30, 2025

Acurx Pharmaceuticals Receives Positive EMA Opinion on Pediatric Investigation Plan for Ibezapolstat in Children with C. difficile Infection, Advancing Toward Phase 3 Trials

Reuters
·
Sep 30, 2025